Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy
Cancer Research and Treatment. 2022;54(4):1219-1229 
Chemotherapy for Primary and Recurrent Epithelial Ovarian Cancer
Ovarian Cancer - From Pathogenesis to Treatment. 2018;
Multiple lines of chemotherapy in recurrent epithelial ovarian cancer, are more lines better? A decision analytic model
Gynecologic Oncology. 2014;133:147
Abstract number 6: Multiple lines of chemotherapy in recurrent epithelial ovarian cancer, are more lines better? A decision analytic model
Gynecologic Oncology. 2014;134(2):431-432
2758 Is there a survival benefit for patients who receive post-operative adjuvant chemotherapy following secondary cytoreductive surgery (SCRS) for recurrent epithelial ovarian cancer (EOC)?
European Journal of Cancer. 2015;51:S550
Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?
Clinical Ovarian Cancer. 2010;3(1):36-40
<p>Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?</p>
Cancer Management and Research. 2020;Volume 12:11631-11638
Is there a survival benefit associated with intraperitoneal chemotherapy after neoadjuvant chemotherapy for optimally debulked epithelial ovarian cancer patients?
Gynecologic Oncology. 2017;145:101
Optimizing Management of Recurrent Epithelial Ovarian Cancer with Non–Platinum-Based Chemotherapy
Clinical Ovarian Cancer. 2008;1(2):139-140
Chemotherapy for Recurrent Ovarian Cancer in the Elderly Patients
Ovarian Cancer in Elderly Patients. 2016;63-68